

ASX RELEASE

Sienna Secures \$1.7M From Placement

Melbourne, Australia, 6 December 2019: [Sienna Cancer Diagnostics Ltd \(ASX:SDX\)](#) ("Sienna" or "the Company"), a medical technology company developing and commercialising innovative IVD tests, is pleased to announce the successful completion of a share placement to institutional and sophisticated investors. The Company received \$1,657,185.74. A total of 47,348,164 ordinary shares were issued today at a price of 3.5 cents per share, with 18,442,647 shares issued under ASX listing rule 7.1 and 28,905,517 shares issued under ASX listing rule 7.1A.

As disclosed on 29 November 2019, Sienna will offer shareholders who were recorded on the share register on 4 December 2019 (**Record Date**) the opportunity to participate in a rights issue offer at the share price of the placement, 3.5 cents per share. Eligible shareholders will be forwarded the rights issue documentation and their personalised offer and acceptance form this week. Eligible shareholders can also apply for additional shares in excess of their rights using the personalised form. The allocation of additional shares is at the discretion of the Board of Sienna.

The funds raised from these capital raising initiatives will be used to:

- Accelerate the commercialisation of SIEN NET™
- Fund co-development expenditures for:
 - o Development of a pancreatic cancer test with Minomic International Ltd; and
 - o Development of an exosome based therapeutic for the treatment for Critical Limb Ischemia with VivaZome Pty Ltd;
- provide funding for the continued evaluation of potential technologies for acquisition or in-licence;
- provide additional working capital;
- pay the expenses of the placement and rights offer.

ENDS.

For further information, please contact:

Carl Stubbings, CEO/Managing Director
Sienna Cancer Diagnostics Ltd
cstubbings@siennadiagnostics.com.au
+61 3 8288 2141

Tony Di Pietro, CFO/Company Secretary
Sienna Cancer Diagnostics Ltd
tdipietro@siennadiagnostics.com.au
+61 3 8288 2141

The release of this announcement was authorised by Geoff Cumming, Chairman





About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna's strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners.

The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.

Sienna's most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.